BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23651417)

  • 1. Waldenström macroglobulinaemia: the key questions.
    D'Souza A; Ansell S; Reeder C; Gertz MA
    Br J Haematol; 2013 Aug; 162(3):295-303. PubMed ID: 23651417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waldenström macroglobulinaemia.
    Ghobrial IM; Gertz MA; Fonseca R
    Lancet Oncol; 2003 Nov; 4(11):679-85. PubMed ID: 14602248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waldenström macroglobulinaemia.
    Fonseca R; Hayman S
    Br J Haematol; 2007 Sep; 138(6):700-20. PubMed ID: 17672883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia.
    Gustine JN; Meid K; Hunter ZR; Xu L; Treon SP; Castillo JJ
    Br J Haematol; 2018 Feb; 180(4):578-581. PubMed ID: 27748515
    [No Abstract]   [Full Text] [Related]  

  • 5. Current treatment options for Waldenström macroglobulinemia.
    Vijay A; Gertz MA
    Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waldenström's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.
    Wang W; Lin P
    Pathology; 2020 Jan; 52(1):6-14. PubMed ID: 31767130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waldenström macroglobulinemia.
    Gertz MA
    Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].
    Timár B
    Magy Onkol; 2017 Mar; 61(1):6-11. PubMed ID: 28273183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
    Vitolo U; Ferreri AJ; Montoto S
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis and treatment of Waldenström's macroglobulinemia.
    Louw VJ; Webb MJ
    Transfus Apher Sci; 2010 Apr; 42(2):193-7. PubMed ID: 20117052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2019 Feb; 94(2):266-276. PubMed ID: 30328142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification in Waldenström macroglobulinemia.
    Morel P; Merlini G
    Expert Rev Hematol; 2012 Apr; 5(2):187-99. PubMed ID: 22475287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia.
    Mullen EC; Wang M
    Clin J Oncol Nurs; 2007 Feb; 11(1):87-95. PubMed ID: 17441400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable remission of large B-cell lymphoma transformed from lymphoplasmacytic lymphoma/Waldenström macroglobulinemia successfully treated with sequential immunochemotherapy followed by reduced-intensity allogeneic stem cell transplantation.
    Yamamoto R; Takaori-Kondo A; Kanda J; Imada K; Ichinohe T; Ishikawa T; Ohmori K; Uchiyama T
    Bone Marrow Transplant; 2008 Mar; 41(6):591-3. PubMed ID: 18071292
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
    Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
    Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
    Ansell SM; Kyle RA; Reeder CB; Fonseca R; Mikhael JR; Morice WG; Bergsagel PL; Buadi FK; Colgan JP; Dingli D; Dispenzieri A; Greipp PR; Habermann TM; Hayman SR; Inwards DJ; Johnston PB; Kumar SK; Lacy MQ; Lust JA; Markovic SN; Micallef IN; Nowakowski GS; Porrata LF; Roy V; Russell SJ; Short KE; Stewart AK; Thompson CA; Witzig TE; Zeldenrust SR; Dalton RJ; Rajkumar SV; Gertz MA
    Mayo Clin Proc; 2010 Sep; 85(9):824-33. PubMed ID: 20702770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.
    Castillo JJ; Garcia-Sanz R; Hatjiharissi E; Kyle RA; Leleu X; McMaster M; Merlini G; Minnema MC; Morra E; Owen RG; Poulain S; Stone MJ; Tam C; Varettoni M; Dimopoulos MA; Treon SP; Kastritis E
    Br J Haematol; 2016 Oct; 175(1):77-86. PubMed ID: 27378193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.